Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach

7. července 2020 aktualizováno: Jeffrey Newcorn, Icahn School of Medicine at Mount Sinai
The growing number of medications used to treat attention-deficit/hyperactivity disorder (ADHD) raises important questions about whether different medications have similar or different therapeutic mechanisms of action. We have recently shown that the stimulant methylphenidate (MPH) and the non-stimulant atomoxetine (ATX) produce clinical improvement via a common mechanism in motor cortex, and distinct actions in frontostriatal and midline cingulate-precuneus regions. These exciting findings offer a window into the common and unique neurophysiological mechanisms of response to stimulant and non-stimulant treatments. However, the interpretation and clinical utility of these results would be greatly enhanced by in-depth investigation of the impact of the two treatments on relevant neural networks, and analyses which evaluate whether improvement is achieved via normalization or other adaptive changes in brain function.

Přehled studie

Postavení

Dokončeno

Podmínky

Intervence / Léčba

Detailní popis

The specific aims of this project are to use functional magnetic resonance imaging (fMRI) to determine the significance of activation changes over treatment related to clinical improvement, and the impact of treatment on neural connectivity within and between the anti-correlated frontostriatal 'task-positive' circuit and cingulate-precuneus 'task-negative' network. Our central hypotheses are that clinical improvement is associated with: (i) normalization of reduced connectivity of regions within the 'task-positive' network, with resultant increased inhibition of motor cortex, and (ii) normalization of low task-related connectivity in regions within the task-negative network for MPH and the 'task-positive' network for ATX.

This research proposes to test a model which posits a neurophysiological basis of mechanisms of response to stimulant and non-stimulant medications, and fits with our long term objectives of being able to match treatments to individual patients. Testing this model requires large samples of youth scanned using fMRI before and after treatment, and matched healthy controls also scanned twice. We will use an innovative network-based approach to study the effects of treatment, building on results from our current fMRI treatment study, and incorporating new theoretical approaches to understanding ADHD and its treatment.

Typ studie

Intervenční

Zápis (Aktuální)

127

Fáze

  • Fáze 4

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

  • Spojené státy
    • New York
      • New York, New York, Spojené státy, 10029
        • Icahn School of Medicine at Mount Sinai

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

7 let až 17 let (Dítě)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

General inclusion criteria for subjects with ADHD and healthy controls are:

  • aged 7-17 years;
  • Wechsler Intelligence Scale for Children (WISC) scores ≥ 75;
  • informed consent and assent to study participation.

Specific inclusion criteria for youth with ADHD are:

  • diagnosis of ADHD, any subtype, determined by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Aged Children-Present and Lifetime Versions (K-SADS-PL);
  • ADHD Rating Scale-IV-Parent Version: Investigator Administered (ADHD-RSIV) total score ≥ 1.5 SD above age and gender means for subtype
  • Clinical Global Impressions-ADHD-Severity (CGI-S) score > 4;
  • ADHD must be the primary diagnosis and focus of treatment, and the treatments offered in the study must not be contraindicated for the comorbid disorder.

Exclusion Criteria:

General exclusion criteria are:

  • history of head injury with loss of consciousness or any CNS disease that is likely to affect brain function;
  • diagnosis of autism or pervasive developmental, psychotic, major mood, and Tourette's disorder;
  • alcohol or drug abuse in the past 3 months or a positive urinary toxic screen on initial evaluation;
  • use of psychotropic medication within 2 weeks of the study (8 weeks for fluoxetine);
  • pre-existing medical or psychological condition which precludes being in the scanner (e.g., claustrophobia, morbid obesity);
  • metal in the body that precludes scanning (e.g., braces, metal plate);
  • positive urine pregnancy test.

Specific exclusion criteria for the treatment trial include:

  • previous unsuccessful trial of MPH or ATX that was adequately dosed (≥ 1 mg/kg for MPH or 1.0 mg/kg for ATX) and of adequate duration (≥ 4 weeks);
  • abnormal findings on physical exam, or vital signs
  • pulse and blood pressure > 95% of age and gender mean;
  • inability to swallow capsules;
  • weight is < 20 kg or > 85 kg.

Specific exclusion criteria for control youth include:

  • no past history or current diagnosis of any psychiatric disorder, determined by the K-SADS-PL interview;
  • ADHD-RS-IV and CBCL scores for each symptom domain ≤ 1 SD of age and gender means.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Čtyřnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Aktivní komparátor: fMRI scans
Healthy Control Group: will receive initial evaluation, and 2 fMRI (functional magnetic resonance imaging) scans each 6-8 weeks apart
Jiný: fMRI scans
2 fMRI scans 6-8 weeks apart
Experimentální: Atomoxetine arm
These subjects will receive initial evaluation and baseline fMRI scan, flexible dose titration with atomoxetine for 6-8 weeks, and fMRI postscan, with optional post study stabilization visits.
Jiný: fMRI scans
2 fMRI scans 6-8 weeks apart
Lék: Atomoxetine arm
Flexible dose titration with atomoxetine prescribed at weekly visits for 6-8 weeks
Ostatní jména:
  • Strattera
  • ATX
Experimentální: Methylphenidate arm
Subjects will receive initial evaluation, baseline fMRI scan, flexible dose titration with methylphenidate (Concerta) for 6-8 weeks, and fMRI scan post treatment.
Jiný: fMRI scans
2 fMRI scans 6-8 weeks apart
Lék: Methylphenidate arm
Flexible dose titration with methylphenidate for 6-8 weeks, with optional post study stabilization visits.
Ostatní jména:
  • Koncert
  • MPH

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Percentage of Correct Inhibition in Participants Assessed With the Go-No go Task
Časové okno: Baseline and at 6 weeks
Comparison of Go-Nogo at 6 weeks from baseline. Performance on a go-nogo task inside the scanner (fMRI). In the go/no-go task, participants respond to certain stimuli ("go" stimuli) and make no response for others ("no-go" stimuli).
Baseline and at 6 weeks

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Adult Attention Deficit Hyperactivity Disorder Investigator Symptom Rating Scale (ADHD-RS)
Časové okno: 8 weeks
ADHD-RS is an 18-item list of core ADHD symptoms, each item are scored on a 4-point scale from 0-3, with total 0-54, with higher score indicating more symptoms.
8 weeks
Clinical Global Impressions-Severity (CGI-S)
Časové okno: up to 6 weeks
a clinician rated measure of symptom severity. CGI-S is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
up to 6 weeks
Response Time in Attention Networks Test (ANT)
Časové okno: baseline and at 6 weeks
A neuropsychological assessment of attention compared at 6 weeks from baseline by looking at response time. The ANT is a task designed to test three attentional networks in children and adults: alerting, orienting, and executive control. The response time were summed.
baseline and at 6 weeks
Continuous Performance Test (CPT)
Časové okno: baseline and at 6 weeks
A neuropsychological assessment of attention compared at 6 weeks from baseline. CPT is a task-oriented computerized assessment of attention-related problems.This score indicates the number of times the client responded but no target was presented. A fast reaction time and high commission error rate points to difficulties with impulsivity. A slow reaction time with high commission and omission errors, indicates inattention in general. Scores are compared with the normative scores for the age, group and gender of the person being tested and represented as a commissioned T-score. The T-score indicates the degree to which performance in CPT task is higher or lower than the performance of a healthy individual matched in age. A T-score of 50 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of more attention-related problems.
baseline and at 6 weeks
Digit Span
Časové okno: baseline and at 6 weeks
A cognitive/neuropsychological measure of auditory/verbal working memory compared at 6 weeks from baseline. Digit Span. Memory span is the longest list of items that a person can repeat back in correct order immediately after presentation on 50% of all trials. Items may include words, numbers, or letters. The task is known as digit span when numbers are used. Memory span is a common measure of short-term memory. A digit-span task is used to measure working memory's number storage capacity.The item score is the sum of the scores on the two trials for that item (range=0-2). The total raw score for backwards digit span is the sum of the item scores; maximum backwards digit span total raw score is 0-16 points. Higher score indicates better health outcomes.
baseline and at 6 weeks
Finger Windows
Časové okno: baseline and at 6 weeks
A neuropsychological measure of motor skill and visual-spatial working memory compared at 6 weeks from baseline. The Finger Windows subtest is a measure of nonverbal, rote sequential recall. scaled scores ranging from 1 to 19, with higher score indicating better attention or concentration.
baseline and at 6 weeks

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Icahn School of Medicine at Mount Sinai

Spolupracovníci

National Institute of Mental Health (NIMH)

Vyšetřovatelé

  • Vrchní vyšetřovatel: Kurt Schulz, PhD, Icahn School of Medicine at Mount Sinai

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia

1. října 2012

Primární dokončení (Aktuální)

30. dubna 2018

Dokončení studie (Aktuální)

30. dubna 2018

Termíny zápisu do studia

První předloženo

30. srpna 2012

První předloženo, které splnilo kritéria kontroly kvality

30. srpna 2012

První zveřejněno (Odhad)

3. září 2012

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

24. července 2020

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

7. července 2020

Naposledy ověřeno

1. července 2020

Více informací

Termíny související s touto studií

Klíčová slova

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • GCO 11-0161
  • 5R01MH095766-02 (Grant/smlouva NIH USA)

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na ADHD

Klinické studie na fMRI scans

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Colombia

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

Předplatit